OpenAI Explores Massive Funding Round at $750 Billion Valuation 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Uppsala, Sweden, Nov. 02, 2016 -- Oasmia Pharmaceutical AB (NASDAQ:OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company and also significantly improved the interest terms.
The current loan from Nexttobe amounts to MSEK 94.4 and is due on December 31, 2016. The new loan replaces the current at due date and amounts, including the accrued interest for 2016, to MSEK 102.4 in total, and is due for payment on September 30, 2017. The interest for the new loan is set at 3.5 %.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Julian Aleksov Tel: +46 18 50 54 40 E-mail: [email protected]
